Wells Fargo & Company MN Sells 727 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Wells Fargo & Company MN trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,944 shares of the biopharmaceutical company’s stock after selling 727 shares during the quarter. Wells Fargo & Company MN’s holdings in Intra-Cellular Therapies were worth $3,169,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the period. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 4th quarter valued at $96,000. Wilmington Savings Fund Society FSB bought a new position in Intra-Cellular Therapies in the 3rd quarter worth $97,000. Barlow Wealth Partners Inc. purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth $184,000. Finally, R Squared Ltd bought a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $205,000. Institutional investors own 92.33% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on ITCI. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Monday. They set a “hold” rating for the company. Piper Sandler reissued a “neutral” rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Eleven analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Stock Performance

Shares of ITCI opened at $131.87 on Wednesday. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98. The company’s fifty day simple moving average is $130.92 and its 200-day simple moving average is $107.03. The company has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.